



**Biocon Limited**  
20th KM Hosur Road  
Electronics City  
Bangalore 560 100 India  
T 91 80 2808 2808  
F 91 80 2852 3423

[www.biocon.com](http://www.biocon.com)

Date: March 17, 2016

The Manager  
Dept. of Corporate Services – Listing  
The Bombay Stock Exchange Limited  
P J Tower, Dalal Street  
Mumbai – 400 001

The Manager- Listing Department  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra – East,  
Mumbai - 400051

Dear Sir,

**Sub: Agreement for development and commercialisation of rh-Insulin for US market**


We wish to inform you that the Company has, through its wholly owned subsidiary Biocon SA, entered into a co-development and commercialisation agreement with M/s Laboratorios PiSA S.A. de C.V (PiSA) of Mexico for generic recombinant human insulin (rh-insulin) for the US market. This is a cost and profit sharing agreement with Biocon SA being responsible for clinical development, regulatory approvals, and commercialization of the product in the US. The drug substance will be made by Biocon while the drug product will be made by PiSA at its facility in Mexico.

The Company has arranged an investor call on March 17, 2016 at 4 pm (dial in details provided below) to address any queries from investors / analysts related to this transaction.

Dial-in Numbers: Primary Number	<b>+91 22 3938 1081</b>
Secondary Number	<b>+91 22 6746 5891</b>
Conference Number / ID	<b>18391</b>
Replay Facility	The replay will be available after the call ends. <b>Replay available till March 20, 2016.</b> Dial in number: +91 22 3065 2322/ 6181 3322 Playback ID: 44711

Request you to kindly take the above intimation on record.

Thanking you.

Yours faithfully,  
For Biocon Limited,  
  
Authorized Signatory

